Loading

Please wait...

Sabril

Generic Name: vigabatrin (vye GA ba trin)
Brand Names: Sabril, Vigadrone
Sabril (vigabatrin) is an anti-epileptic medication used to treat complex partial seizures. Includes Sabril side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Sabril

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Sabril (Vigabatrin) is an anti-epileptic medicine, also called an anticonvulsant. Sabril is used in combination with other medications to treat complex partial seizures in adults and children who are at least 10 years old. The powder for oral solution is used to treat infantile spasms in babies and children between the ages of 1 month and 2 years. Sabril can cause serious side effects and should be used only by people who have been unable to control their seizures with several other medications. Learn more

Sabril Side Effects

Sabril Side Effects

Note: This document contains side effect information about vigabatrin. Some of the dosage forms listed on this page may not apply to the brand name Sabril.

In Summary

Common side effects of Sabril include: arthralgia, blurred vision, confusion, depression, diplopia, fatigue, weight gain, abnormal gait, ataxia, cough, diarrhea, drowsiness, memory impairment, tremor, irritability, and pharyngolaryngeal pain. Other side effects include: status epilepticus, urinary tract infection, pulmonary congestion, abnormality in thinking, asthenia, depressed mood, dysmenorrhea, erectile dysfunction, eye pain, muscle twitching, paresthesia, peripheral edema, sinus headache, abnormal behavior, abnormal sensory symptoms, anemia, back pain, bronchitis, chest pain, constipation, fever, hypoesthesia, hyporeflexia, lethargy, myalgia, nervousness, nystagmus disorder, peripheral neuropathy, sedated state, toothache, upper abdominal pain, vertigo, malaise, abnormal dreams, bruise, and increased appetite. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to vigabatrin: oral powder for solution, oral tablet

Warning

Oral route (Powder for Solution; Tablet)

Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, vigabatrin may also decrease visual acuity.Risk increases with increasing dose and cumulative exposure, but there is no dose or exposure to vigabatrin known to be free of risk of vision loss.Risk of new and worsening vision loss continues as long as vigabatrin is used, and possibly after discontinuing vigabatrin.Baseline and periodic vision assessment is recommended for patients on vigabatrin. However, this assessment cannot always prevent vision damage.Vigabatrin is available only through a restricted program called the Vigabatrin REMS Program. Further information is available at www.vigabatrinREMS.com or 1-866-244-8175.

Along with its needed effects, vigabatrin (the active ingredient contained in Sabril) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking vigabatrin:

More common

  • Blue-yellow color blindness
  • blurred vision
  • decreased vision or other vision changes
  • eye pain
  • increase in seizures
  • loss of memory
  • problems with memory

Less common or rare

  • Uncontrolled rolling eye movements

Get emergency help immediately if any of the following symptoms of overdose occur while taking vigabatrin:

Symptoms of overdose

  • Change in or loss of consciousness

Some side effects of vigabatrin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Agitation
  • burning, tingling, or prickly sensations
  • clumsiness or unsteadiness
  • confusion
  • constipation
  • diarrhea
  • dizziness
  • double vision or seeing double
  • increased movement
  • joint pain
  • mental depression
  • sleepiness or unusual drowsiness
  • stomach pain
  • trembling
  • tremor
  • trouble sitting still

Less common

  • Aggression
  • headache
  • increased saliva
  • muscle weakness
  • nausea
  • poor concentration
  • speech disorder
  • trouble sleeping
  • unusual thoughts
  • vomiting
  • weight gain

For Healthcare Professionals

Applies to vigabatrin: oral powder for reconstitution, oral tablet

General

The more commonly reported adverse reactions have included headache, somnolence, fatigue, dizziness, weight gain, tremor and visual field defects. This drug can cause permanent vision loss.

Ocular

Based on adult studies, 30 percent or more of patients can be affected with bilateral concentric visual field constriction ranging in severity from mild to severe. Severe cases may be characterized by tunnel vision to within 10 degrees of visual fixation, which can result in disability. In some cases, damage can occur to the central retina and may decrease visual acuity.

Very common (10% or more): Visual field defect (30% or more), nystagmus (up to 19%), blurred vision (up to 16%), diplopia (up to 16%)

Common (1% to 10%): Asthenopia, eye pain, strabismus, conjunctivitis

Rare (0.01% to 0.1%): Retinal disorder (such as peripheral retinal atrophy)

Very rare (less than 0.01%): Optic neuritis, optic atrophy

Nervous system

Very common (10% or more): Headache (up to 33%), somnolence (up to 26%), dizziness (up to 26%), tremor (up to 16%), memory impairment (up to 16%), abnormal coordination (up to 16%)

Common (1% to 10%): Speech disorder, sensory disturbance, paresthesia, movement disorder (including dystonia, dyskinesia, and hypertonia), either alone or in association with abnormalities in MRI, hyperreflexia, hyporeflexia, hyperesthesia, hypoesthesia, status epilepticus, dysarthria, postical state, sensory loss

Uncommon (0.1% to 1%): Coordination abnormal (ataxia)

Rare (0.01% to 0.1%): Encephalopathy (e.g., sedation, stupor, confusion)

Frequency not reported: Increase in seizure frequency

Postmarketing reports: Dystonia, encephalopathy, hypertonia, hypotonia, muscle spasticity, myoclonus, optic neuritis, dyskinesia

Magnetic Resonance Imaging (MRI) Abnormalities in Infants:

-Abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in some infants treated with this drug for infantile spasms. Some infants exhibited coincident motor abnormalities, but no causal relationship has been established.

Dermatologic

Common (1% to 10%): Acne

Uncommon (0.1% to 1%): Rash

Rare (less than 0.1%): Angioedema, urticaria

Postmarketing reports: Facial edema, angioedema, maculo-papular rash, pruritus, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), alopecia

Psychiatric

Very common (10% or more): Excitation (children), agitation (children)

Common (1% to 10%): Agitation, aggression, nervousness, depression, paranoid reaction, irritability, asthenia, fever, thirst, malaise, expressive language disorder, abnormal dreams, mental impairment (thought disturbance), lethargy, disturbance in attention

Uncommon (0.1% to 1%): Hypomania, mania, psychotic disorder

Rare (0.01% to 0.1%): Suicide attempt

Very rare (less than 0.01%): Hallucination

Postmarketing reports: Acute psychosis, apathy, delirium, hypomania, neonatal agitation, psychotic disorder

Metabolic

Very common (10% or more): Weight gain (up to 14%)

Common (1% to 10%): Increased appetite

Other

Very common (10% or more): Fatigue (up to 40%), gait disturbance (up to 12%)

Common (1% to 10%): Edema, tinnitus, vertigo, peripheral edema

Postmarketing reports: Deafness, malignant hyperthermia, multi-organ failure

Hematologic

Common (1% to 10%): Anemia

Endocrine

Postmarketing reports: Birth Defects, delayed puberty, developmental delay

The following birth defects have been reported during the postmarketing period: congenital cardiac defects, congenital external ear anomaly, congenital hemangioma, congenital hydronephrosis, congenital male genital malformation, congenital oral malformation, congenital vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, and talipes.

Gastrointestinal

Very common (10% or more): Diarrhea (up to 16%), nausea (up to 10%)

Common (1% to 10%): Vomiting, abdominal pain, upper abdominal pain, constipation, dyspepsia, stomach discomfort, toothache, abdominal distention, thirst

Postmarketing reports: Gastrointestinal hemorrhage, esophagitis

Genitourinary

Common (1% to 10%): Urinary tract infection, dysmenorrhea, erectile dysfunction

Hepatic

Very rare (less than 0.01%): Hepatitis

Frequency not reported: Decreases in ALT and AST

Postmarketing reports: Cholestasis

Musculoskeletal

Very common (10% or more): Arthralgia

Common (1% to 10%): Joint sprain, muscle strain, back pain, pain in extremity, myalgia, muscle twitching, muscle spasms

Respiratory

Very common (10% or more): Upper respiratory tract infection (up to 51%) Nasopharyngitis (up to 14%), pharyngeal pain (up to 14%), cough (up to 14%)

Common (1% to 10%): Bronchitis, pulmonary congestion, sinus headache

Postmarketing reports: Laryngeal edema, pulmonary embolism, respiratory failure, stridor

Cardiovascular

Common (1% to 10%): Chest pain

Immunologic

Very common (10% or more): Viral infection (up to 20%), pneumonia (up to 13%)

Common (1% to 10%): Influenza

Uncommon (0.1% to 1%): Candidiasis, ear infection, croup infectious

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Sabril (www.drugs.com/sabril.html).